JHL Biotech, Inc., a provider of biopharmaceutical process development and manufacturing...
One of the reasons for the strong adaption rate of single use systems stems from the ability to...
GE Healthcare Life Sciences, and JHL Biotech today announced that GE Healthcare has completed...
This first episode of The Daily Dose from Pharmaceutical Processing discusses the technology driving single use systems and why this methodology has had such an impact. Two specific benefits discussed here include limiting cross-contamination risk and reducing changeover times.
Ready-to-go straight from the box, ÄKTA start is a compact, affordable protein purification system that removes the hassles of manual approaches and provides automated control of the purification procedure.
Stratus Media Group, Inc., announced today the closing of its acquisition of two biopharmaceutical companies - Canterbury Laboratories, LLC, and Hygeia Therapeutics, Inc.
BioValves are designed to minimize flow path turbulence and be used single handed. Molded from glass reinforced Nylon USP Class VI, the thread pitch is calibrated to 2mm per turn, ensuring accurate fluid transfer rates.
The Bio Tube Applicator is a pneumatic device enabling operators to effortlessly connect barbs, filters and other single use components, at the touch of a button. The unit eliminates the need for alcohol based lubricants in assembly while potentially reducing the risk of operator repetitive strain injuries by removing the need for manual force.
These cryogenic valves are suitable for high-pressure, low-temperature liquified natural gas (LNG), manufacturing, heat treating and vaporizing applications to -420F.
These microprocessor-controlled PCR workstations reduce risk of sample contamination during DNA/RNA amplification and manipulation.
This new device is designed to meet the demand for more flask clamp sizes suitable for holding a wider variety of sample sizes.
This mechanical self-setting valve switch reduces calibration time, especially during instances of diaphragm change-out and valve commissioning.
The compact, multiport double weir design of this diaphragm valve provides for multiple flow paths while reducing contact surfaces and hold up volume.
Each of these ductless chemical fume hoods has advanced safety monitoring and controls and is ASHRAE 110 tested.
A new type of "good cholesterol," made in the lab, could one day deliver drugs to where they are needed in the body to treat disease or be used in medical imaging, according to scientists. Their report on the high-density lipoprotein (HDL) mimic, which is easy to make in large amounts, appears in the journal ACS Nano.
These biocontainers provide fluid integrity performance in 2D & 3D configurations, in volumes from 50 mL to 1,000 L, to accommodate R&D through production needs.
RQC Series flexible tubing connectors are designed for single use systems.
Biosimilars have received a lot of attention and “buzz” lately. And, as the FDA continues to hold meetings and put out documents for comment as it decides just how to eventually approve and regulate these biopharm generics there is one question that needs to be addressed.
The FDA/EMEA has introduced initiatives to advocate real-time, in-line monitoring of critical parameters in the manufacturing process, rather than testing the end product. This article discusses the application of a new sensor technology which provides real-time insight into nutrient consumption and product expression enabling manufacturers to automate and optimize closed loop control of the feeding regime of their media.
Amgen will focus on the integration and strategy behind its acquisition of Onyx Pharmaceuticals, which makes two cancer drugs and has others in testing, when it reports third-quarter results late Tuesday.
The October issue of Pharmaceutical Processing profiles Catalent’s new clinical biologics manufacturing facility in Madison, Wisconsin. The role of quality control and microscopy services for the industry is also featured in this issue as well as an article on Brazil’s emerging pharmaceutical manufacturing industry.
Biopharmaceuticals continue to be a growing, important class of pharmaceutical products on the market, and many of these products are produced using mammalian cell culture. Monoclonal antibodies, currently the dominant class of biopharmaceuticals, generally require mammalian cell culture production to enable addition of critical post-translational modifications such as glycosylation.
Amgen and ShanghaiTech University today announced the two organizations have entered into a memorandum of understanding (MOU) to form a strategic partnership for the advancement of biopharmaceutical discovery and translational research in China. This agreement includes plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University.
GE Healthcare Life Sciences to Build KUBio Modular Biopharmaceutical Factory for JHL Biotech in ChinaSeptember 25, 2013 8:07 am | News | Comments
GE Healthcare Life Sciences and JHL Biotech, a provider of biopharmaceutical process development and manufacturing services, today announced that a KUBio ™ modular biopharmaceutical factory will be built in China for JHL Biotech. The site for the new factory, which will be fully operational beginning early 2015, is the Biolake Science Park in Wuhan, China.
Catalent's clinical-stage biologics facility is a critical part of the company's global capabilities.
Biogen Idec has been added to the prestigious Dow Jones Sustainability World Index becoming the first and only U.S. based biotech sector firm to make the list. The company was also named to the Dow Jones Sustainability Index (DJSI) North America for the fourth consecutive year, one of only three biotech companies included.
The September 2013 issue of Pharmaceutical Processing features a profile of LSNE, a Bedford, NH-based contract manufacturing company that offers a range of lyophilization and fill/finish services. We also take a look at how CMOs are evaluating employee performance to improve operations, and our article on parenteral manufacturing services details some new trends for this important market segment.
The foundations of the biosimilar drug market continue to take shape as drugmakers move forward with their varied and evolving strategies for biosimilar pharmaceutical development, according to a new Fitch Ratings report. The opportunities afforded by the nascent biosimilars market are significant as eight of the 20 best-selling pharmaceutical products in the world are biologics set to lose patent protection by 2020.
- Page 1